Infliximab for patients with refractory ulcerative colitis

Inflammatory Bowel Diseases

Volumn 7, Issue SUPPL. 1, 2001, Pages

  Chey, William Y ^a  

^a Rochester Institute for Digestive Diseases and Sciences   (United States)

Author keywords

Antitumor necrosis factor alpha monoclonal antibody; Inflammatory bowel disease; Infliximab; Ulcerative colitis

Indexed keywords

GASTROINTESTINAL AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; CLINICAL TRIAL; COLONOSCOPY; DRUG ANTAGONISM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

AGED; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; COLONOSCOPY; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0003059415     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1002/ibd.3780070507     Document Type: Article

References (5)

1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. Am J Gastroenterol 1997;92:204-11.
2. Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 1999;28:255-81.
3. Calkins BM. Inflammatory bowel diseases. In: Everhart JE, ed. Digestive Diseases in the United States. Epidemiology and Impact. Bethesda, MD: National Institutes of Health, 1994:511-50.
4. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992;14:318-27.
5. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-5.